Michael Opoku, MD
Internal Medicine · Oklahoma City, OKNPI 1578520235
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $690 of the $942 with a category attached, or 73.2%. Boehringer Ingelheim accounts for 73.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $764 and has fallen 94.3% since, to $44 in 2024.
Across 15 payments — averaging $62.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$690
- Merck$99
- Pfizer$47
- Cumberland Pharmaceuticals, Inc.$40
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$19
- Otsuka America Pharmaceutical, Inc.$18
- plus $29 from 2 others
What the payments were for
- Consulting fees$69073%
- Food & beverage$25227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $690 |
| Merck | 4 | $99 |
| Pfizer | 3 | $47 |
| Cumberland Pharmaceuticals, Inc. | 3 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Abbott | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$690
How this compares
$942 in reported general payments places this provider in the 65th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 28 | $74 |
| Pantoprazole Sodium | 14 | $68 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $64 |
| Furosemide | 21 | $63 |
| Levofloxacin | 18 | $59 |
| Oxycodone Hcl | 12 | $53 |
| Carvedilol | 12 | $43 |
| Metoprolol Succinate | 12 | $31 |
| Atorvastatin Calcium | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.